DGM
FATE icon

Darwin Global Management’s Fate Therapeutics FATE Stock Holding History

Darwin Global Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-153,537
Closed -$8.98M – 5
2021
Q4 		$8.98M Sell
153,537
-199,713
-57% -$11.3M 1.37% 7
2021
Q3 		$20.9M Buy
353,250
+17,332
+5% +$1.36M 3.85% 4
2021
Q2 		$29.2M Sell
335,918
-1,034,215
-75% -$83.3M 4.7% 3
2021
Q1 		$113M Buy
1,370,133
+417,286
+44% +$40M 22.12% 3
2020
Q4 		$86.6M Buy
+952,847
New +$59.2M 24.18% 2

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Darwin Global Management's FATE Position: Q1 2022 in Review

Darwin Global Management sold out of Fate Therapeutics (FATE) in Q1 2022, closing a stake of 153,537 shares — an estimated $8.98M sold.

Darwin Global Management first reported a position in FATE in Q4 2020 and held it in 5 quarters. The position peaked at $113M in Q1 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

  • Darwin Global Management reported no remaining Fate Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Darwin Global Management sold 153,537 Fate Therapeutics shares in Q1 2022, an estimated $8.98M.
  • Darwin Global Management first reported a position in Fate Therapeutics in Q4 2020 and held it in 5 quarters.
  • Darwin Global Management's Fate Therapeutics position peaked at $113M in Q1 2021.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on Darwin Global Management's 13F filing for Q1 2022, filed 16 May 2022.